Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingenol Mebutate 0.05% Gel for Verruca Vulgaris
NCT02748902Phase 1Completed
- Start
- Apr 2016
- Primary completion
- Jan 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ingenol mebutate in verruca vulgaris. Primary endpoint: Verruca vulgaris lesion counts at Day 57. Started Apr 2016; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
verruca vulgaris
Beyond the preview
Go deeper on NCT02748902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748902.